Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT06809686
Recruiting Observational

Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care

NCT06809686 · tracked via the Priya Life Science UK tracker
Sponsor
Richmond Research Institute
Phase
Observational
Started
2025-02-05
Last updated
2026-05-20

Condition(s) studied

Heart Failure

Study summary

The purpose of this study is to establish an electrocardiogram (ECG) data library to facilitate future studies on heart disease. Additionally, the study will be used to monitor changes in the patient's standard of care throughout the study period and gather patient perspectives on routine diagnostic procedures and disease monitoring and feedback on the design of heart failure trials.

Eligibility

Sex
ALL
Min age
45 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Male or female participants aged 45 to 80 years (inclusive) at the date of signing the informed consent. 2. Diagnosed with heart failure. 3. Able and willing to provide informed consent to participate. Exclusion Criteria: 1. Diagnostic test results positive for: 1. HIV-1 or HIV-2 infection 2. Hepatitis B or Hepatitis C infection 2. Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or cooperation during the study as judged by the Investigator. 3. Any condition judged by the Investigator to pose an undue risk while participating in the trial 4. Diagnostic results which are inconsistent with heart failure with mildly reduced or preserved ejection fraction as judged by the Investigator.

Primary outcome measure(s)

  • To generate high quality ECG data to establish an ECG library for the development of an ECG tool to monitor disease progression. — 18 months
    After providing informed consent, participants will then undergo a series of clinical assessments, and the participants' ECGs will be used to contribute to establishing an ECG library for future heart disease research.

Trial sites (2)

FacilityCityRegionStatus
Richmond Pharmacology London London Recruiting
Richmond Pharmacology London London Recruiting

More Richmond Research Institute trials in the UK

Engagement Study for Participants With Factor V Leiden and Prothrombin G20210A Mutations Recruiting
Serological and PCR Testing for COVID-19 Recruiting
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease Recruiting
PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY Recruiting

Other trials for the same condition

Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices Active, not recruiting
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) Recruiting
Reduction of Mitral Regurgitation With the SATURN Trans-Septal Transcatheter Mitral Valve Replacement (TMVR) System in Patients With Severe Symptomatic Mitral Regurgitation Recruiting
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation Active, not recruiting
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06809686 on ClinicalTrials.gov ↗ ← All trials in the UK